Report: Data sharing measures improving
Wednesday, September 10, 2014
Citeline, an Informa business unit, has reported that clinical trial transparency, also known as responsible data sharing, is in a much healthier state than shown in previous studies.
“Prior analyses found that 23% to 57% of completed clinical trials do not report results. However, these analyses only included trials that met specific criteria and none included conference abstracts as a source for results disclosure. As such, I wanted to know what the current status is for results reporting among industry sponsors using broader inclusion criteria and across multiple sources for results,” said Doro Shin, a Citeline analyst.
For her analysis, Shin used Citeline’s Trialtrove, a competitive intelligence resource that draws data from over 30,000 sources. The analysis focused on nearly 7,500 phase II-III industry-sponsored trials with primary completion dates between 2008 and 2012 to determine how many of these trials provided results in peer-reviewed sources (defined as a journal manuscript or conference abstract) or at clinicaltrials.gov.
Of all of the phase II-III studies reviewed, a surprising 78% provided final or interim results across all sources. When looking just at the phase III trials, the most expensive and high-profile trials for sponsors, 81% provided final or interim results.
Shin’s findings also focused on the disclosure rates among the top 20 pharma companies, which range from 55% to 98% when all sources are consulted. Amgen appears to be the most dedicated to reporting, with 98% of its phase III trials in the dataset showing results, followed closely by AstraZeneca and Celgene. Most sponsors report phase III results in both peer-reviewed sources and at clinicaltrials.gov. However, some companies such as Astellas and Roche seem to favor posting their results only in peer-reviewed sources.
“Although sponsor companies are in fact assuming some degree of risk by reporting clinical trial results, either positive or negative,” said Shin, “it is refreshing to see that they are becoming more and more committed to industry initiatives to improve transparency.”
From a competitive intelligence perspective, this improved access to trial results data leads to better informed strategic decisions and increased R&D productivity, provided the right sources are consulted. From an overall societal perspective, it helps provide better information to patients participating in trials and to those who eventually will benefit from new or improved medicines.